Chemotherapy Induced Alopecia Treatment Market Size, Share, and Industry Analysis By Drug (Minoxidil, Deuruxolitinib, Ritlecitinib, and Others), By Route of Administration (Oral and Topical), By Dosage Form (Tablet, Capsule, Foam, and Solution), By End-user (Hospital Pharmacies, Drug Store & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032

The global chemotherapy induced alopecia treatment market is witnessing significant growth due to the rising prevalence of cancer. Chemotherapy involves the administration of medications or drugs for the treatment of cancer. Chemotherapy leads to a significant hair thinning or loss, known as chemotherapy-induced alopecia (CIA). CIA is frequently considered as one of the most troubling side effects of chemotherapy. CIA interventions include some oral and topical agents, such as deuruxolitinib and minoxidil, which are used off-label. Currently, there are no FDA-approved oral or topical agents available for the treatment of chemotherapy-induced alopecia. Due to increasing burden of CIA and lack of approved treatment options, many companies have increased their focus on R&D initiatives for the effective treatment development.

• For example, the drug LH-4 (Topical Coacillium 42%) developed by Legacy Healthcare is currently in a Phase 2 trial. In addition, a topical calcitriol formulation, BPM 31543BPGbio, Inc., developed by BPGbio, Inc., has completed a Phase 1 trial.

Furthermore, the increasing number of population treated with chemotherapy contributes to a higher demand for effective alopecia solutions.

• For instance, as per data provided by the Crown in April 2020, around 28.0% of people were treated with chemotherapy among all cancer-diagnosed patients in England between 2013 and 2016 and 27.0% were treated with radiotherapy.

Chemotherapy Induced Alopecia Treatment Market Driver

Increasing Global Prevalence of Various Cancers to Drive Market Growth

The increasing occurrence of cancer on a global scale is the main factor driving the growth of the chemotherapy induced alopecia treatment market.

• For example, according to information from the World Health Organization (WHO), in February 2024, there were approximately 20.0 million new cancer cases and 9.7 million deaths in 2022. Approximately 53.5 million individuals were living five years after being diagnosed with cancer.

As chemotherapy continues to be a crucial part of cancer treatment, the prevalence of chemotherapy-induced alopecia (CIA) is also rising. As per data published by the National Center for Biotechnology Information (NCBI) in March 2023, around 65% of individuals receiving chemotherapy suffer from hair loss, which greatly affects their quality of life and results in a greater need for successful treatments for alopecia globally.

According to data provided by the American Cancer Society, Inc., the number of new cancer cases in the U.S. increased slightly from 2019 to 2023.

Chemotherapy Induced Alopecia Treatment Market Restraint

High Cost of Alopecia Treating Products May Restrict Market Growth

One of the major restraints for the global chemotherapy induced alopecia treatment market is the high treatment cost of alopecia that occurs due to the chemotherapy. Further, the development of successful treatments for alopecia requires significant research activities and clinical trials, resulting in the increased costs for these therapies.

• For instance, the average cost of ROGAINE topical products ranges from USD 60.0 to USD 103.0. Further, the oral tablet, Leqselvi, used for the treatment of alopecia, costs around USD 202.7. These products are expensive and sometimes unaffordable for individuals in low-income countries.

Chemotherapy Induced Alopecia Treatment Market Opportunity

Approval of Pipeline Drugs is Anticipated to Fuel Market Growth in the Coming Years

Due to the growing burden of chemotherapy induced alopecia, several companies have increased their focus on the development and launch of advanced treatment options.

• For example, in June 2019, BPGbio, Inc. participated in the American Society of Clinical Oncology annual meeting conducted in Chicago. During the event, the company presented data regarding Phase 1 results for BPM 31543 drug candidate used in the treatment of chemotherapy-induced alopecia.

In addition, rising investment in alopecia treatment research and an increase in funding for dermatological research signifies the potential introduction of new, more effective treatments, providing significant opportunities for market players operating in the chemotherapy induced alopecia treatment market.

Key Insights

The report covers the following key insights:

• Prevalence of Cancer, By Key Countries, 2023


• Pipeline Analysis, By Key Players


• New Product Launches, by Key Players


• Key Industry Developments (Mergers, Acquisitions, Partnerships)


• Impact of COVID-19 on the Market

Segmentation

Analysis by Drug

Based on drug, the chemotherapy induced alopecia treatment market is segmented into minoxidil, deuruxolitinib, ritlecitinib, and others.

The minoxidil segment is anticipated to grow at a significant CAGR over 2024-2032. The growth of the segment is mainly attributed to the increasing regulatory approvals, product launches, and availability of a large number of topical minoxidil formulations in the global market.

• For instance, in September 2021, Dr. Reddy’s Laboratories Ltd. launched a Minoxidil topical solution for the treatment of hair loss in India.

Analysis by Route of Administration

On the basis of route of administration, the market for chemotherapy induced alopecia treatment is divided into oral and topical.

The oral segment held considerable market share in 2023 and is expected to grow at a substantial CAGR during the forecast period. The growth of the segment is mainly attributed to the increasing regulatory approvals and product launches of oral drugs for the treatment of alopecia.

• For instance, in June 2023, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved LITFULO (ritlecitinib), a once-daily oral treatment, for adults and individuals above 12 years of age with severe alopecia areata.

Analysis by Dosage Form

On the basis of dosage form, the market is fragmented into tablet, capsule, foam, and solution.

The solution segment is expected to grow at a considerable CAGR during the forecast period. The increasing initiatives by market players for the development of topical solutions for the treatment of alopecia is one of the factors driving segmental growth.

• For example, in June 2023, Cosmo Pharmaceuticals announced that, it had started phase III trials of Clascoterone topical solution in males for the treatment of androgenetic alopecia (AGA).

Analysis by Distribution Channel

Based on distribution channel, the market for chemotherapy induced alopecia treatment is categorized into drug store & retail pharmacies, hospital pharmacies, and online pharmacies.

 The hospital pharmacies segment held a substantial market share in 2023. The segment growth is mainly due to the increasing prevalence of cancer and the rising number of people undergoing chemotherapy.

• For example, as per data provided by the American Journal of Managed Care (AJMC) in May 2019, from 2018 to 2040, the annual global number of patients in need of initial chemotherapy is projected to rise by 53.0%, reaching 15.0 million from 9.8 million.

Furthermore, the online pharmacies segment held a considerable market share in 2023 and is expected to grow at a notable CAGR from 2024 to 2032. In recent times, there has been a rise in online shopping, including the purchasing of both prescribed and over-the-counter drugs. Online pharmacies and drug sales have been well-liked globally for nearly two decades. The popularity of online pharmacies has increased in recent years, with predictions indicating that this trend will persist.

Regional Analysis

To gain extensive insights into the market, Request for Customization

By region, the market for chemotherapy induced alopecia treatment has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America held a dominant share of the global chemotherapy-induced alopecia (CIA) treatment market in 2023. Advanced healthcare infrastructure, coupled with an increasing number of chemotherapy procedures, drives market growth in this region. Furthermore, increasing regulatory approvals for the launch of pharmaceutical products that can be used for the treatment of alopecia also propel industry expansion.

• For instance, in June 2022, Eli Lilly and Company announced that it received the U.S. Food and Drug Administration (FDA) approval for OLUMIANT (baricitinib), a once-daily pill for the treatment of severe alopecia areata.

Additionally, the strong pharmaceutical and biotechnology industry in the area drives innovation, resulting in the development of advanced treatments for CIA.

Furthermore, Europe accounted for a substantial market share in 2023. The increasing initiatives by market players for the development of therapy for alopecia and the rising focus of market players on receiving regulatory approvals for alopecia treatment are some of the factors driving market growth in the region.

Key Players Covered

The global chemotherapy induced alopecia treatment market is highly fragmented, with the presence of large number of players accounting for a smaller proportion.

The report includes the profiles of the following key players:

• Sun Pharmaceutical Industries Ltd. (India)     


• Pfizer Inc. (U.S.)


• Eli Lilly and Company (U.S.)


• Taro Pharmaceutical Industries Ltd. (Israel)


• Legacy Healthcare (U.S.)


• BPGbio, Inc. (U.S.)


• Johnson & Johnson Services, Inc. (U.S.)


• Cosmo Pharmaceuticals (Ireland)

Key Industry Developments

• In July 2024, Sun Pharmaceutical Industries Ltd. announced that it received the U.S. Food and Drug Administration (FDA) approval of Leqselvi (deuruxolitinib) for the treatment of severe alopecia areata.

• In May 2024, Soterios Pharma, a U.K.-based clinical-stage life sciences company, announced new positive topline results from its randomized, placebo-controlled, multi-dose, phase 2 clinical trial evaluating STS-01 for the treatment of mild to moderate alopecia areata.


• In September 2023, Pfizer Inc. revealed that the European Commission (EC) approved LITFULO (ritlecitinib) for adults with severe alopecia areata.